Development of an Imaging Prediction Model for Pelvic Lymph Node Metastasis of Cervical Cancer Using Artificial Intelligence Techniques.
NCT ID: NCT06448897
Last Updated: 2024-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
4000 participants
OBSERVATIONAL
2024-02-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective Cohort Study Comparing AI Prediction Model With Imaging Assessment to Diagnose Lymph Node Metastasis in Cervical Cancer
NCT06541288
Exploratory Study on NIRFI Technology Combined with ICG Guided Cervical Cancer Lymph Node Metastasis
NCT06840418
Sentinel Lymph Node Mapping In Cervical Cancer
NCT03778268
Artificial Intelligence Enables Precision Diagnosis of Cervical Cytology Grades and Cervical Cancer
NCT04551287
Sentinel Lymph Nodes Biopsy in Cervical Cancer
NCT06169787
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age ≥18 years old and ≤80 years old
3. patients with complete preoperative pelvic MRI images and postoperative pathology and clinical data in our hospital
Exclusion Criteria
2. Patients who have received neoadjuvant chemotherapy or radiotherapy before surgery for this previous cervical cancer
3. Patients with other malignant tumors within 5 years
4. Combination of other underlying diseases that may lead to enlarged pelvic lymph nodes
5. Imaging report more than 1 month prior to surgery
6. Poor image quality and unrecognizable
18 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Obstetrics & Gynecology Hospital of Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Obstetrics and Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FUOBGY2024-33
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.